Isoindole-imide compounds, compositions, and uses thereof

Details Isoindole-imide compounds, compositions, and uses thereof Isoindole-imide compounds, compositions, and uses thereof

2006-08-15

2006-08-15

Chang, Celia (Department: 1625)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

C546S193000, C546S201000, C514S323000

Reexamination Certificate

active

07091353

ABSTRACT:
The invention relates to isoindole-imide compounds and pharmaceutically acceptable salts, hydrates, solvates, clathrates, enantiomers, diastereomers, racemates, or mixtures of stereoisomers thereof, pharmaceutical compositions comprising these isoindole-imide compounds, and methods for reducing the level of cytokines and their precursors in mammals. In particular, the invention pertains to isoindole-imide compounds that are potent inhibitors of the production of TNF-α in mammals. The isoindole-imides described herein are useful for treating or preventing diseases or disorders in mammals, for example, cancers, such as solid tumors and blood-born tumors; heart disease, such as congestive heart failure; osteoporosis; and genetic, inflammatory; allergic; and autoimmune diseases.

REFERENCES:
patent: 3992189 (1976-11-01), Goddard
patent: 5045108 (1991-09-01), Elbe et al.
patent: 5198402 (1993-03-01), Kaji et al.
patent: 5326800 (1994-07-01), Horn et al.
patent: 5385901 (1995-01-01), Kaplan et al.
patent: 5605914 (1997-02-01), Muller
patent: 5635517 (1997-06-01), Muller et al.
patent: 5658940 (1997-08-01), Muller et al.
patent: 5698579 (1997-12-01), Muller
patent: 5703098 (1997-12-01), Muller et al.
patent: 5728845 (1998-03-01), Muller et al.
patent: 5736570 (1998-04-01), Muller et al.
patent: 5798368 (1998-08-01), Muller et al.
patent: 5801195 (1998-09-01), Muller et al.
patent: 5874448 (1999-02-01), Muller et al.
patent: 5877200 (1999-03-01), Muller
patent: 5929117 (1999-07-01), Muller et al.
patent: 5955476 (1999-09-01), Muller et al.
patent: 5968945 (1999-10-01), Muller et al.
patent: 6011050 (2000-01-01), Muller et al.
patent: 6020358 (2000-02-01), Muller et al.
patent: 6046221 (2000-04-01), Muller et al.
patent: 6075041 (2000-06-01), Muller
patent: 6130226 (2000-10-01), Muller et al.
patent: 6180644 (2001-01-01), Muller et al.
patent: 6200987 (2001-03-01), Muller
patent: 6214857 (2001-04-01), Muller et al.
patent: 6395754 (2002-05-01), Muller et al.
patent: 0 797 437 (1997-10-01), None
patent: 1 004 572 (2000-05-01), None
patent: 1 004 580 (2000-05-01), None
patent: 1 004 581 (2000-05-01), None
patent: WO 92/18496 (1992-10-01), None
patent: WO 95/01348 (1995-01-01), None
patent: WO 96/20705 (1996-07-01), None
patent: WO 96/20926 (1996-07-01), None
patent: WO 97/08143 (1997-03-01), None
patent: WO 97/12859 (1997-04-01), None
patent: WO 97/23457 (1997-07-01), None
patent: WO 97/37988 (1997-10-01), None
patent: WO 97/45117 (1997-12-01), None
patent: WO 98/03502 (1998-01-01), None
patent: WO 98/06692 (1998-02-01), None
patent: WO 98/24763 (1998-06-01), None
patent: WO 98/41525 (1998-09-01), None
patent: WO 98/54170 (1998-12-01), None
patent: WO 99/06041 (1999-02-01), None
patent: WO 99/46258 (1999-09-01), None
patent: WO 99/47512 (1999-09-01), None
patent: WO 00/25777 (2000-05-01), None
patent: WO 00/38521 (2000-07-01), None
patent: WO 00/55134 (2000-09-01), None
Bundgaard “Design of prodrugs”Elsevier, p. 27-43 (1985).
Foster “The functions of cytokines . . . ”CA 136:230735 (2001).
Vecchiarelli “Cytokines and costimulatory . . . ”CA 135:286931 (2000).
Naik et al. “The hydrolysis of . . . ”CA 118:131893 (1993).
Joseph et al. “Macrophage role in . . . ”J. Nati. Can. Inst. v. 90, p. 1648-1653 (1998).
Schmahl et al. “The enantiomers of the teratogenic htalidomide . . . ”CA 110:822 (1989).
Corral et al., 1999, “Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-α”, J Immunol.163:380-386.
He et al., 1993, “Synthesis of thalidomide analogs and their biological potential for treatment of graft versus host disease”, Abstracts of Papers, 206thACS National Meeting, Abstract No. 216.
Muller et al., 1996, “Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity”, J. Med. Chem. 39:3238-3240.
Muller et al., 1998, “Thalidomide analogs and PDE4 inhibition” Bioorg. Med. Chem. Lett. 8:2669-2674.
Muller et al., 1999, “Amino-substituted thalidomide analogs: potent inhibitors of TNF-α production”, Bioorg. Med. Chem. Lett. 9:1625-1630.
Bundgaard, “Design of prodrugs” Elsevier, Amsterdam - New York - Oxford, p. 27-43 (1986).
Corral et al., 1996, “Selection of novel analogs of thalidomide with enhanced tumor necrosis factor alpha inhibitory activity” Mol. Med. Jul;2(4):506-15.
Database CAPLUS on STN (Columbus, OH, USA), No. 118:131893, ‘The hydrolysis of azidoprofen esters: a model for a soft anti-inflammatory drug for topical application’ Int. J. Phar. Vol. 89, p. 65-74 (1993), abstract.
Database CAPLUS on STN (Columbus, OH, USA), No. 128:140615, ‘Substituted 2-(2,6-dioxo-3-piperidinyl)phthalimides and 1-oxoisoindolines and method of reducing TNF-alpha levels’WO98/03502, abstract and registry no. 191732-76-0, 202271-87-2, 202271-88-3, 202271-89-4, 202271-90-7.
Database CAPLUS on STN (Columbus, OH, USA), No. 130:38290, ‘Substituted 2-(2,6-dioxo-3-piperidinyl)phthalimides and 1-oxoisoindolines and method of reducing TNF-alpha levels’ WO98/54170, abstract and registry no. 202271-88-3, 216669-27-1; 191732-72-6.
Database CAPLUS on STN (Columbus, OH, USA), No. 131:214197, ‘Preparation of 2-(2,6-dioxo3-fluoropiperidin-3-yl) isoindolines for reducing inflammatory cytokine levels’ US 5,955,476, abstract and registry no. 220460-56-0, 220460-57-1, 220460-62-8, 220460-64-0.
Marriott et al., 2001, “Immunotherapeutic and antitumor potential of thalidomide analogue” Expert Opin. Biol. Ther. Jul;1(4):675-82. Review.
Miyachi et al. 1998, “Tumor necrosis factor-alpha production enhancing activity of substitued 3′-methylthalidomide: influence of substituents at the phthaloyl moiety on the activity and stereoselectivity” Chem. Pharm. Bull. (Tokyo). Jul;46(7):1165-8.
Price et al., 2002, “5′-OH-thalidomide, a metabolite of thalidomide, inhibits angiogenesis” Ther. Drug monit. Feb;24(1):104-10.
Naik, et al., “The hydrolysis of azidoprofen: A model for a soft anti-inflammatory drug for topical application”, International Journal of Pharmaceutics, 1993, Vol. 89, pp. 65-74.

Affiliated with

Also associated with

Rating

Isoindole-imide compounds, compositions, and uses thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Isoindole-imide compounds, compositions, and uses thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Isoindole-imide compounds, compositions, and uses thereof will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3623482